Profile of:

Nurullah Akkoc

Full name: Nurullah Akkoc

Current country: Turkey

Membership level: Full

Type of membership: Member

Number of publications: 15

Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis. (2021)

European bio-naïve spondyloarthritis patients initiating TNFi: Time trends in baseline characteristics, treatment retention and response (2021)

Do mobility exercises in different environments have different effects in ankylosing spondylitis? (2021)

JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold? (2021)

Assessing rheumatologists’ attitudes and utilization of classification criteria for ankylosing spondylitis and axial spondyloarthritis: a global effort (2021)

Is Axial Spondyloarthritis More Common Than Rheumatoid Arthritis? (2020)

The adaptation of the Turkish version of the Assessment of Knowledge in Ankylosing Spondylitis Patients by a Self-Administered Questionnaire (2020)

Prevalence of Spondyloarthritis Among Patients Who Underwent Lumbar Disc Herniation Surgery (2020)

Development of ASAS quality standards to improve the quality of health and care services for patients with axial spondyloarthritis. (2020)

Genome-wide association study in Turkish and Iranian populations identify rare familial Mediterranean fever gene (MEFV) polymorphisms associated with ankylosing spondylitis (2019)

Measurement properties of the ASAS Health Index: results of a global study in patients with axial and peripheral spondyloarthritis (2018)

Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals Of Care for UveitiS (FOCUS) Initiative (2018)

An Assessment in SpondyloArthritis International Society (ASAS)-endorsed definition of clinically important worsening in axial spondyloarthritis based on ASDAS (2018)

Do major histocompatibility complex tag single nucleotide polymorphisms accurately identify HLA-B27 in the Turkish population? (2017)

Therapies of Early, Advanced, and Late Onset Forms of Axial Spondyloarthritis, and the Need for Treat to Target Strategies (2017)